WO2011132051A3 - Tricycle compounds as phosphodiesterase-10 inhibitors - Google Patents
Tricycle compounds as phosphodiesterase-10 inhibitors Download PDFInfo
- Publication number
- WO2011132051A3 WO2011132051A3 PCT/IB2011/000846 IB2011000846W WO2011132051A3 WO 2011132051 A3 WO2011132051 A3 WO 2011132051A3 IB 2011000846 W IB2011000846 W IB 2011000846W WO 2011132051 A3 WO2011132051 A3 WO 2011132051A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phosphodiesterase
- inhibitors
- tricycle
- compounds
- tricycle compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
The present invention provides Phosphodiesterase- 10 inhibitors. In particular, tricyclic derivatives described herein are useful as Phosphodiesterase- 10 inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by Phosphodiesterase- 10. (Formula I) (I)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1273MU2010 | 2010-04-19 | ||
IN1273/MUM/2010 | 2010-04-19 | ||
US32929910P | 2010-04-29 | 2010-04-29 | |
US61/329,299 | 2010-04-29 | ||
IN3314/MUM/2010 | 2010-12-06 | ||
IN3314MU2010 | 2010-12-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011132051A2 WO2011132051A2 (en) | 2011-10-27 |
WO2011132051A3 true WO2011132051A3 (en) | 2012-01-19 |
Family
ID=44834563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/000846 WO2011132051A2 (en) | 2010-04-19 | 2011-04-18 | Tricycle compounds as phosphodiesterase-10 inhibitors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011132051A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012112946A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
CN103755715B (en) * | 2013-12-26 | 2015-12-09 | 武汉理工大学 | Cumarone is [2,3-c] pyridine compounds and synthetic method thereof also |
GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
GB201803340D0 (en) * | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
CN108892616A (en) * | 2018-08-31 | 2018-11-27 | 凯莱英生命科学技术(天津)有限公司 | Prepare continuous device and its application of benzaldehydes intermediate |
CN110003227B (en) * | 2019-04-26 | 2022-03-11 | 新乡市润宇新材料科技有限公司 | Synthetic method of 2-methyl-8-methoxybenzofuran [2,3-b ] pyridine |
CN111499540B (en) * | 2020-04-22 | 2022-09-27 | 中南民族大学 | Method for preparing 2,4,6-trichlorobenzonitrile by ammoxidation method, special catalyst and preparation method |
CN115677637B (en) * | 2022-09-27 | 2024-02-23 | 安徽秀朗新材料科技有限公司 | Simple preparation method of 1-bromodibenzofuran |
CN117143108B (en) * | 2023-08-31 | 2024-03-19 | 蒲城欧得新材料有限公司 | 8-bromo-2-methylbenzofuran [2,3-b ] pyridine and synthetic method |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004037805A1 (en) * | 2002-10-23 | 2004-05-06 | Glenmark Pharmaceuticals Ltd. | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
WO2004089940A1 (en) * | 2003-04-11 | 2004-10-21 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
WO2006011024A2 (en) * | 2004-07-19 | 2006-02-02 | Glenmark Pharmaceuticals Ltd. | New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
WO2006064355A2 (en) * | 2004-12-17 | 2006-06-22 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders |
WO2008032171A1 (en) * | 2006-09-11 | 2008-03-20 | Matrix Laboratories Ltd. | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
WO2009081222A1 (en) * | 2007-12-21 | 2009-07-02 | Glenmark Pharmaceuticals, S.A. | Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands |
-
2011
- 2011-04-18 WO PCT/IB2011/000846 patent/WO2011132051A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004037805A1 (en) * | 2002-10-23 | 2004-05-06 | Glenmark Pharmaceuticals Ltd. | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
WO2004089940A1 (en) * | 2003-04-11 | 2004-10-21 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
WO2006011024A2 (en) * | 2004-07-19 | 2006-02-02 | Glenmark Pharmaceuticals Ltd. | New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
WO2006064355A2 (en) * | 2004-12-17 | 2006-06-22 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders |
WO2008032171A1 (en) * | 2006-09-11 | 2008-03-20 | Matrix Laboratories Ltd. | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
WO2009081222A1 (en) * | 2007-12-21 | 2009-07-02 | Glenmark Pharmaceuticals, S.A. | Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands |
Also Published As
Publication number | Publication date |
---|---|
WO2011132051A2 (en) | 2011-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011132051A3 (en) | Tricycle compounds as phosphodiesterase-10 inhibitors | |
CA2871471C (en) | Dna-pk inhibitors | |
WO2009156462A3 (en) | Organic compounds | |
WO2012125488A8 (en) | C4-monomethyl triterpenoid derivatives and methods of use thereof | |
WO2008132139A3 (en) | New heterocyclic derivatives useful for the treatment of cns disorders | |
WO2013049726A3 (en) | Processes for making compounds useful as inhibitors of atr kinase | |
MX2011008864A (en) | Sulfonylated tetrahydroazolopyrazines and their use as medicinal products. | |
WO2009111653A3 (en) | Antiviral therapeutic agents | |
WO2011069063A3 (en) | Multicyclic compounds and methods of use thereof | |
WO2012016186A8 (en) | Macrocyclic kinase inhibitors and uses thereof | |
WO2012118812A3 (en) | Substituted 6,5-fused bicyclic heteroaryl compounds | |
WO2008152099A3 (en) | Aryl/hetarylamides as modulators of the ep2 receptor | |
CA2830549C (en) | Methods and compositions for preparing noribogaine from voacangine | |
PH12015500211B1 (en) | 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | |
WO2012083306A3 (en) | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | |
WO2010150211A3 (en) | Use of derivatives of indoles for the treatment of cancer | |
WO2009115084A3 (en) | Pyrrolopyrimidine derivatives, and use thereof | |
WO2010129918A8 (en) | Triptolide prodrugs | |
MX2016007128A (en) | Ccr6 compounds. | |
WO2013040227A3 (en) | Therapeutic compounds | |
WO2010049449A3 (en) | Novel salts of sunitinib | |
WO2012162513A3 (en) | Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors | |
WO2010089327A3 (en) | Indole derivatives as anticancer agents | |
WO2010077730A3 (en) | Indanone inhibitors of acetylcholinesterase | |
WO2010007482A3 (en) | Thiazole derivatives as stearoyl coa desaturase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11771658 Country of ref document: EP Kind code of ref document: A2 |